Avalo Therapeutics Statistics
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
6.76+0.01 (+0.15%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Avalo Therapeutics by the numbers
Avalo Therapeutics has a market capitalization of $390.9 million based on 57.82M shares outstanding. With trailing EPS of $-2.26, Avalo Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 39.7% below its 50-day average and 56.2% below its 200-day average.
Average daily trading volume is 1.80M shares, or about $12.2 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
AVTX valuation vs. peer median
| Metric | AVTX | Peer median | Difference |
|---|---|---|---|
| Market cap | $390.88M | $389.50M | +0% |
| Avg. volume | 1.80M | 963.48K | +87% |
Peer median across 8 companies: OCS, IRD, PHAT, OVID, PBYI, CRMD, ASPE, PRTA.
Valuation
- Market cap
- $390.88M
- Price / sales (latest FY)
- 6,625.15
- EPS (TTM)
- $-2.26
- Shares outstanding
- 57.82M
Price and trading
- Previous close
- 6.75
- Open
- 6.65
- Day range
- 6.61 – 7.03
- 52-week range
- 6.53 – 24.27
- 52-week change
- -62.09%
- Beta
- —
- Volume
- 1.18M
- Average volume
- 1.80M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 390.88M
- Forward Pe
- -2.58
- Eps
- -2.26
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 24.27
- Week52 Low
- 6.53
- Avg Volume
- 1.80M
- Shares Outstanding
- 57.82M
- Ma50
- 11.21
- Ma200
- 15.43
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -72.15%
- Pct From52w Low
- 3.52%